MINYANVILLE ORIGINAL Shares of Gilead Sciences (NASDAQ:GILD) are rising after the drug maker said a combination of its therapies were 100% effective in curing a small group of previously untreated patients for hepatitis C. The finding and other data will be presented at a medical meeting in Boston this week. Abbott Laboratories (NYSE:ABT) showed that it is neck and neck with Gilead in the race for a better hepatitis C therapy by announcing its own impressive results over the weekend. Abbott said it cured 97.5% of patients who had not previously been treated with any drugs for the liver-wasting ...